175 related articles for article (PubMed ID: 36183289)
1. Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.
Tsaur I; Blaheta RA; Dotzauer R; Brandt MP; Gandaglia G; Sinescu I; Mirvald C; Olivier J; Surcel C;
World J Urol; 2023 Aug; 41(8):2077-2090. PubMed ID: 36183289
[TBL] [Abstract][Full Text] [Related]
2. Current evidence on local therapy in oligometastatic prostate cancer.
Basourakos SP; Henning G; Karnes RJ
Curr Opin Urol; 2024 May; 34(3):198-203. PubMed ID: 38305293
[TBL] [Abstract][Full Text] [Related]
3. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
4. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.
Jalfon MJ; Sakhalkar OV; Lokeshwar SD; Marks VA; Choksi AU; Klaassen Z; Leapman MS; Kim IY
Curr Urol Rep; 2023 Oct; 24(10):455-461. PubMed ID: 37369828
[TBL] [Abstract][Full Text] [Related]
5. A narrative review of oligometastatic prostate cancer-an evolving paradigm.
Sritharan K; Rieu R; Tree A
Ann Palliat Med; 2021 May; 10(5):5969-5987. PubMed ID: 33752437
[TBL] [Abstract][Full Text] [Related]
6. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Baboudjian M; Roubaud G; Fromont G; Gauthé M; Beauval JB; Barret E; Brureau L; Créhange G; Dariane C; Fiard G; Mathieu R; Ruffion A; Rouprêt M; Renard-Penna R; Sargos P; Ploussard G;
World J Urol; 2023 Aug; 41(8):2033-2041. PubMed ID: 36484817
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
[TBL] [Abstract][Full Text] [Related]
8. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
10. Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?
Rao A; Vapiwala N; Schaeffer EM; Ryan CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():309-320. PubMed ID: 31099652
[TBL] [Abstract][Full Text] [Related]
11. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
12. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.
Aluwini SS; Mehra N; Lolkema MP; Oprea-Lager DE; Yakar D; Stoevelaar H; van der Poel H; ; Busstra M; de Jong IJ; de Reijke T; de Vries K; Heijmink S; Jenster G; Klaver S; Kneppers J; Lavalaye J; Leyten G; Moonen L; Nagaraj J; Noordzij W; Osanto S; Oving I; Schaake E; Scheenen T; Schoots I; Sedelaar M; Somford D; van den Berkmortel F; van der Hulle T; van der Voort van Zyp J; van Leeuwen P; van Moorselaar J; van Oort I; Vogel W; Westgeest H
Eur Urol Oncol; 2020 Apr; 3(2):231-238. PubMed ID: 31401014
[TBL] [Abstract][Full Text] [Related]
15. Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?
Arcos MBL; López-Campos F; Valcarcel ML; Rubio MG; de Manzanos IVF; Duque-Santana V; Aparicio MG; Martin JZ; Kishan AU; Achard V; Siva S; Couñago F
Clin Genitourin Cancer; 2023 Jun; 21(3):e93-e103. PubMed ID: 36456467
[TBL] [Abstract][Full Text] [Related]
16. [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?].
Steuber T; Maurer T; Miller K
Urologe A; 2021 Dec; 60(12):1534-1545. PubMed ID: 34734294
[TBL] [Abstract][Full Text] [Related]
17. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
[TBL] [Abstract][Full Text] [Related]
20. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
